Eli Lilly to Invest $3.5 Billion in Lehigh Valley Manufacturing Site for Next-Generation Weight-Loss Medicines

The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than ...

February 03, 2026 | Tuesday | News
I Peace Establishes Human iPS Cells Derived From NKT Cells, Expanding Immune Cell Therapy Platform

Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it ha...

February 03, 2026 | Tuesday | News
Illumina Deepens Leadership in Proteomics and Multiomics With Completed SomaLogic Acquisition

Deeply expands leadership in proteomics and multiomics Combined capabilities bring high scalability, flexibility, and affordability into protein an...

February 03, 2026 | Tuesday | News
KORU Medical Receives FDA Clearance for FreedomEDGE® Infusion System to Deliver UCB’s RYSTIGGO® in gMG

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...

February 02, 2026 | Monday | News
Origami Therapeutics and Ipsen Enter Global Collaboration to Advance Disease-Modifying Therapy for Rare Neurodegenerative Disease

- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases ...

February 02, 2026 | Monday | News
Elevar Submits NDA for Lirafugratinib as Second-Line FGFR2-Driven Cholangiocarcinoma Therapy

  Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...

January 30, 2026 | Friday | News
Imviva Biotech’s CTD402 Granted FDA Orphan Drug Designation for Relapsed/Refractory T-ALL/LBL

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, announced that the U.S. Food and Drug ...

January 29, 2026 | Thursday | News
Longeveron Secures FDA Type C Meeting Ahead of Pivotal ELPIS II Data Readout in HLHS

ELPIS II top-line trial results are anticipated in the third quarter of 2026 Laromestrocel Biological License Application (BLA) submission for full tr...

January 28, 2026 | Wednesday | News
Gannet BioChem Acquires Laysan Bio to Expand Activated Polymer and Bioconjugation Capabilities

Gannet BioChem, a leading specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capit...

January 28, 2026 | Wednesday | News
Argo Biopharma and Novartis Dose First Patient in Phase 2b Trial of siRNA Therapy BW-20829

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, announ...

January 27, 2026 | Tuesday | News
HanchorBio and WuXi Biologics Enter Strategic Collaboration to Advance Next-Generation Fusion Proteins

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseas...

January 27, 2026 | Tuesday | News
Eisai and Biogen’s LEQEMBI IQLIK Moves Toward First At-Home Anti-Amyloid Treatment for Alzheimer’s

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing fo...

January 27, 2026 | Tuesday | News
Samsung Bioepis Releases First Quarter 2026 U.S. Biosimilar Market Report

Samsung Bioepis Co., Ltd. released its First Quarter 2026 Biosimilar Market Report, marking the twelfth edition of the Quarterly Biosimilar Market Report...

January 26, 2026 | Monday | Company results
ADLM Launches Data Science in Laboratory Medicine Certificate Program to Advance Data-Driven Care

The Association for Diagnostics & Laboratory Medicine (ADLM) announced the launch of its Data Science in Laboratory Medicine Certificate Program, des...

January 23, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close